# Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

> **NCT05789056** · PHASE2,PHASE3 · RECRUITING · sponsor: **Quoin Pharmaceuticals** · enrollment: 20 (estimated)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** QRX003, 4% Lotion

## Key facts

- **NCT ID:** NCT05789056
- **Lead sponsor:** Quoin Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789056, "Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05789056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*